Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends aripiprazole

NICE's FAD recommends the use of Bristol-Myers Squibb's atypical anti-psychotic drug Abilify (aripiprazole) as an option for the treatment of adolescent schizophrenia

The National Institute for Health and Clinical Excellence's (NICE) Final Appraisal Determination (FAD) has recommended the use of Abilify (aripiprazole) as an option for the treatment of schizophrenia in people aged 15 to 17 years who are intolerant of risperidone, or for whom risperidone is contraindicated, or whose schizophrenia has not been adequately controlled with risperidone.

Aripiprazole received its first EU approval in 2004. In the UK it is the only commonly-used atypical anti-psychotic licensed for the treatment of adolescent schizophrenia and the first to be appraised by NICE.

The announcement of NICE's forthcoming guidance, which will offer patients in the UK access to a cost-effective treatment for their condition, has been welcomed by patient groups.

According to Marjorie Wallace, CBE, chief executive of mental health charity, SANE: "Everyone's biochemistry differs and the more we can find a choice of medications to target individual needs, with side-effects that can be tolerated, the more we can help people to manage their condition."

"This is particularly important in teenagers: schizophrenia often strikes at this time and it is vital to find effective treatment and prevent relapse, With better medications and therapies, the lives of young people with schizophrenia can be greatly improved," Wallace said.

1st December 2010

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

OPEN Health Graduates and the XP Support Group
During our graduate induction period in September 2018, we were asked to find a charity that could benefit from the expertise of the OPEN Health practices. We made the decision...
Alexander Devine Website has gone live!
As part of the OPEN Health CSR programme one of the charities we support is Alexander Devine. They are a local Children's Hospice based in Maidenhead who provide a truly...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics